Table 2 Comparison of clinical outcomes.

From: Age-stratified comparison of clinical outcomes between medical and surgical treatments in patients with unilateral primary aldosteronism

 

Older (Age ≥ 65 y)

Younger (Age < 65 y)

ADX N = 96

MRA N = 57

p-value

ADX N = 526

MRA N = 176

p-value

Complete clinical success, n (%)

16 (37) (n = 43)

–

–

185 (55) (n = 335)

–

0.02

Partial clinical success, n (%)

13 (30) (n = 43)

–

–

93 (28) (n = 335)

–

 

Absent clinical success, n (%)

14 (33) (n = 43)

–

–

57 (17) (n = 335)

–

 

Complete biochemical success, n (%)

53 (77) (n = 69)

–

–

316 (77) (n = 410)

–

0.96

Hyperkalemia, n (%)

15 (16) (n = 94)

1 (1.8) (n = 56)

 < 0.01

28 (5.5) (n = 514)

3 (1.7) (n = 175)

0.05

Proteinuria, n (%) (6 or 12 months)

7 (11) (n = 62)

6 (17) (n = 35)

0.54

29 (8.8) (n = 331)

15 (13) (n = 117)

0.20

Cardiovascular event, n (%) (during 36 months)

6 (6.7) (n = 90)

6 (11) (n = 54)

0.37

6 (1.2) (n = 499)

5 (3.0) (n = 169)

0.16

  1. Values are n (%). The p-values of clinical success or complete biochemical success represent the comparison between older and younger patients treated with ADX. ADX, adrenalectomy; MRA, mineralocorticoid receptor antagonist.
Back to article page